Story perspectives

Neuralink Launches Clinical Trial for Thought-to-Text Implants

9/20/2025

23 2

Summary

Story summary

Neuralink will start a clinical trial in October to test its brain implant's thought-to-text capabilities for individuals with speech impairments.
The U.S. FDA has approved an investigational device exemption for this trial.
The company plans to enable healthy individuals to receive implants within 3-4 years.
Neuralink is conducting five additional trials to help paralyzed patients control computers.
Long-term goals include implanting devices in 20,000 people annually by 2031 and developing consumer technology.

1 of 1

Story summary

Neuralink will start a clinical trial in October to test its brain implant's thought-to-text capabilities for individuals with speech impairments.
The U.S. FDA has approved an investigational device exemption for this trial.
The company plans to enable healthy individuals to receive implants within 3-4 years.
Neuralink is conducting five additional trials to help paralyzed patients control computers.
Long-term goals include implanting devices in 20,000 people annually by 2031 and developing consumer technology.